

18 September 2019

ASX Code: MXC

## 200 Prescription Milestone Passed in Australia & United Kingdom with Increasing Patient Uptake

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based 'Seed to Pharmacy' bio-pharma company specialising in the production and development of phytocannabinoid derived medicines, is pleased to announce that it has substantially increased the number of patients prescribed to date its standardised, affordable medicines to pass the 200 prescription mark, delivering a material increase to the first 100 patients registered or prescribed milestone announced in mid-August 2019.

### Key Highlights:

- 52 new patients added during first 2 weeks of September in Australia, the average number of new patients increasing on a weekly basis with regular supply channels in place
- Following to the announcement dated 14 August 2019, over 100 additional MGC Pharma products have been prescribed in Australia and the UK over the past month, taking the total prescriptions to date to +200
- This new, key milestone demonstrates MGC Pharma's proprietary standardised, affordable medicines and the Company's increasing distribution capabilities
- MGC Pharma's products, CannEpi<sup>®</sup> and MXP100 (100mg/mL cannabidiol), prescribed in Australia under the Special Access Scheme and in the UK through specialised doctors permitted to prescribe phytocannabinoid derived medicines under the Early Access to Medicines Scheme.
- CannEpi<sup>®</sup> is the Company's high CBD, low THC formula (20:1) phytocannabinoid derived formulation targeting the treatment of drug resistant epilepsy
- Increasing uptake of patients and number of prescriptions is testament to the quality and cost competitiveness of MGC Pharma's EU-GMP grade phytocannabinoid derived medicines
- Cannabis Access Clinics joins Tetra Health as one of the Company's key clinic partners

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** "Having already achieved 200 prescriptions across our first key markets of Australia and the United Kingdom is a fantastic achievement for the Company and a validation of our 'Seed to Pharmacy' strategy. This has been achieved within months of establishing new key distribution networks for our first products to market, both in Australia and the UK. Having progressed CannEpi<sup>®</sup> and MXP100 from the Research & Development stages through to commercialisation, we now have a proven process in which we can advance additional standardised, affordable phytocannabinoid derived medicines.

"Critically, with our unique EU-GMP production and key market distribution infrastructure now established, we can meet this increasing demand for our offering of phytocannabinoid derived medicines in our existing and future markets. We anticipate the uptake of patients to continue to increase accordingly, providing revenue to invest further in new production and our Research & Development strategies, as well as cementing MGC Pharma has a key player in the medical cannabis sector globally."

**Further Information**

Increasing the number of prescribed MGC Pharma phytocannabinoid derived medicines to over 200 across Australia and the UK demonstrates the rapid uptake of the Company’s products and its strengthening position in each market. In addition, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research. The commercialisation of its portfolio of phytocannabinoid derived medicines is in line with its strategy of becoming a world-leading bio-pharma company through international distribution agreements.

CannEpi<sup>®</sup> and MXP100 are both proprietary MGC Pharma products that have been developed internally through the Company’s Research and Development division and progressed through to commercialisation. This is in line with the Company’s ‘Seed to Pharmacy’ strategy with the Company owning all the intellectual property through each stage of a product’s development, from the genetics to finished pharmaceutical grade product.

The Company continues to work closely with its designated distributors to onboard further clinics, in addition to independent medical professionals, in each region increasing patient access to its phytocannabinoid derived medicines under the relevant legislation in each jurisdiction.

MGC Pharma’s designated UK distributors are Grow Biotech PLC, a British headquartered company developing revolutionary processes, practices, techniques, tools and formulations to bridge the gap between existing cannabis medicines and accepted pharmaceutical standards, and IPS Specials, a company that manufactures unlicensed compounded medications and formulations for community and hospital pharmacists, and dispensing doctors. Grow Biotech and IPS provide direct, official access into the UK medical cannabis market with an extensive network of some 5,500 pharmacies across the UK.

In Australia, MGC Pharma has appointed Health House International and Cannvalate as its regional distributors. Health House International is an Australian-based specialist medicinal cannabis company that wholesales and distributes medicinal cannabis products to community and hospital pharmacies. Cannvalate is Australia’s largest network of cannabis prescribers and dispensaries (1,000+ doctors and 600+ pharmacies) giving the Company immediate and Australia-wide access to patients across all specialties.

The Company’s products have also been recently on-boarded by Tetra Health and Cannabis Access Clinics into their catalogue of available products provided to their networks of medical professionals.

Tetra Health streamlines patient access, provides education on how to prescribe cannabis for medical purposes to medical practitioners, and manages treatment outcomes with specialist nurses across Australia. Tetra Health, through its founders and network of partners, has managed over 30,000 global patients and has seen a 500% increase in patient growth in Australia over the last month. Cannabis Access Clinics (CAC) is a Southern Cannabis Holdings company and is the largest network of medicinal cannabis clinics in Australia. CAC work directly with patients who suffer from indications for which there is some evidence that medicinal cannabis therapies may be beneficial. They work in accordance with TGA Guidance documents on medicinal cannabis, consulting patients with a number of indications.

Import and export approval for MGC Pharma products is granted per shipment to both Australia and UK. This process requires approvals from both the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) and the Office of Drug Control (ODC) for Australia, similarly between JAZMP and the United Kingdom Home Office Drugs Licencing and Compliance Unit for the UK, with the process now established and streamlined for future shipments. As is typical in the industry, payment terms are 90 days from the time of sale of MGC Pharma products by the distributor and therefore all sales will be reflected in the financial report of the Company in the quarter following the date that sales are contracted.

--Ends--

**For further information, please contact:**

**UK IR/Media Advisors**

Gaby Jenner/ Catherine Leftley

St Brides Partners Ltd

+44 (0) 207 236 1177

[gaby@stbridespartners.co.uk](mailto:gaby@stbridespartners.co.uk)

[catherine@stbridespartners.co.uk](mailto:catherine@stbridespartners.co.uk)

**MGC Pharmaceuticals Ltd**

Brett Mitchell

Executive Chairman

+61 8 6382 3390

[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting three widespread medical conditions - epilepsy, dementia and IBS – and has further products in the development pipeline.

Employing its 'Seed to Pharmacy' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia and the UK and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,000m<sup>2</sup> GMP state of the art facility in Malta.

Follow us through our social media channels    